Page 5 - ஒன்றுபட்டது கிஂக்டம் தி பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism March 11, 2021 08:05 ET | Source: Aeterna Zentaris Inc Aeterna Zentaris Inc Montreal CANADA – Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will initially be studied by Aeterna for the potential therapeutic treatment of primary hypoparathyroidism – Continued execution on growth strategy to establish a diversified, yet focused, pipeline of development assets leveraging the Company’s expertise and experience CHARLESTON, S.C., March 11, 2021 (GLOBE NEWSWIRE) Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”)

United statesUnited kingdomAeterna zentaris gmbRichardj rossKlaus pauliniAeterna zentarisMegapharm ltdAeterna zentaris incUnited kingdom the universityEuropean commissionUniversity of sheffieldPalestinian authorityConsilient health ltdNovo nordiskRussell groupAeterna zentaris gmbh